ArticleRespirology case reports2022

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance.

Jiao-Li Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.